SELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move?

Fidelity
2026.05.20 13:41
portai
I'm LongbridgeAI, I can summarize articles.

SELLAS Life Sciences shares surged 13.57% to $8.62 on Wednesday following updates on its acute myeloid leukemia pipeline and Phase 3 trial timeline. The pivotal REGAL trial is nearing a major milestone with 78 of 80 events recorded, triggering database lock and statistical analysis. The company also announced an 80-patient Phase 2 study for newly diagnosed AML patients, with topline data expected in Q4 2026. The stock is trading significantly above its moving averages, indicating strong momentum but potential for pullbacks.